AR and pachyonychia congenita: Many patients with rising prostate-specific antigen (PSA) levels eventually progress to castration-resistant PC (CRPC), often associated with persistent androgen receptor (AR) signaling, despite maintaining castrate concentrations of serum testosterone, defined as <50 ng/dL [13, 14].